Cargando…

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients

BACKGROUNDS AND PURPOSE: Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yan, Gan, Qinyi, Lai, Rongtao, Wang, Weijing, Guo, Simin, Sheng, Zike, Chen, Lu, Guo, Qing, Cai, Wei, Wang, Hui, Zhao, Gangde, Cao, Zhujun, Xie, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801606/ https://www.ncbi.nlm.nih.gov/pubmed/35111690 http://dx.doi.org/10.3389/fcimb.2021.733348

Ejemplares similares

Male zooid extracts of Antheraea pernyi ameliorates non-alcoholic fatty liver disease and intestinal dysbacteriosis in mice induced by a high-fat diet
por: Zhu, Lin, et al.
Publicado: (2022)

Ecological shifts of salivary microbiota associated with metabolic-associated fatty liver disease
por: Wang, Min, et al.
Publicado: (2023)

Shifts in the Bacterial Community of Supragingival Plaque Associated With Metabolic-Associated Fatty Liver Disease
por: Zhao, Fen, et al.
Publicado: (2020)

The Microbiota and It’s Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease
por: Gu, Congwei, et al.
Publicado: (2022)

Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
por: Fang, Jie, et al.
Publicado: (2022)

Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease
por: Jin, Li-ting, et al.
Publicado: (2023)

Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function
por: Yu, Shenglan, et al.
Publicado: (2022)

Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice
por: Rom, Oren, et al.
Publicado: (2019)

Corrigendum: The Microbiota and It’s Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease
por: Gu, Congwei, et al.
Publicado: (2022)

Commentary: Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial
por: Wang, Jieyi, et al.
Publicado: (2022)

Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease
por: Niu, Chenguang, et al.
Publicado: (2023)

Gut Microbiota, Glucose, Lipid, and Water-Electrolyte Metabolism in Children With Nonalcoholic Fatty Liver Disease
por: Pan, Xiongfeng, et al.
Publicado: (2021)

Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
por: Xue, Lanfeng, et al.
Publicado: (2022)

Brain-gut-liver axis: Chronic psychological stress promotes liver injury and fibrosis via gut in rats
por: Xu, Meng-Yang, et al.
Publicado: (2022)

Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease
por: Yu, Jiake, et al.
Publicado: (2021)

Oral-Gut Microbiome Analysis in Patients With Metabolic-Associated Fatty Liver Disease Having Different Tongue Image Feature
por: Lu, Chenxia, et al.
Publicado: (2022)

Automated assessment of steatosis in murine fatty liver
por: Sethunath, Deepak, et al.
Publicado: (2018)

Effects of Zhishi Daozhi Decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet
por: Bi, Chao-Ran, et al.
Publicado: (2023)

Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease
por: Guo, Wen, et al.
Publicado: (2021)

Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids
por: Sun, QinMei, et al.
Publicado: (2022)

Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome
por: Chen, Li-Da, et al.
Publicado: (2019)

Pathology and molecular mechanisms of Schistosoma japonicum-associated liver fibrosis
por: Liu, Zhilong, et al.
Publicado: (2022)

Association Between Skeletal Muscle Mass and Severity of Steatosis and Fibrosis in Non-alcoholic Fatty Liver Disease
por: Guo, Wen, et al.
Publicado: (2022)

Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
por: Nadinskaia, Maria, et al.
Publicado: (2021)

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022)

Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice
por: Wan, Sizhe, et al.
Publicado: (2020)

Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
por: Jiang, Meng, et al.
Publicado: (2019)

Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Qu, Ying, et al.
Publicado: (2021)

SUMO-specific protease 3 is a key regulator for hepatic lipid metabolism in non-alcoholic fatty liver disease
por: Liu, Yuhan, et al.
Publicado: (2016)

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases
por: Shabangu, Ciniso Sylvester, et al.
Publicado: (2020)

Hypercapsule is the cornerstone of Klebsiella pneumoniae in inducing pyogenic liver abscess
por: Hu, Dakang, et al.
Publicado: (2023)

Prognostic Potential of Liver Enzymes in Patients With COVID-19 at the Leishenshan Hospital in Wuhan
por: Liu, Zeming, et al.
Publicado: (2021)

Alterations of lower respiratory tract microbiome and short-chain fatty acids in different segments in lung cancer: a multiomics analysis
por: Zhang, Yong, et al.
Publicado: (2023)

The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis
por: Zhang, Yu-Lin, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

Gut Microbiome and Serum Metabolome Analyses Identify Unsaturated Fatty Acids and Butanoate Metabolism Induced by Gut Microbiota in Patients With Chronic Spontaneous Urticaria
por: Wang, Detong, et al.
Publicado: (2020)

Metagenome Analysis of the Bacterial Characteristics in Invasive Klebsiella Pneumoniae Liver Abscesses
por: Zhang, Zhijie, et al.
Publicado: (2022)

Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease
por: Ayoub, Fares, et al.
Publicado: (2018)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study
por: Ciećko-Michalska, Irena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_75kacmh7k2fsmmprc8vk9320vh